Testosterone side effects in women: pellets vs. other delivery methods

What did @heatherhirschmd actually say?

Dr. Hirsch laid out a hierarchy of testosterone side effects tied to dose: acne first, then hair thinning, and at the far end, permanent changes like voice deepening and clitoral enlargement. Her threshold warning was that levels staying "over 100 or 150" for long periods put women in danger zone territory. She also flagged pellet therapy as particularly prone to these problems, though she didn't go deep on the mechanism in this clip.

The overall message was responsible enough: get the benefits (energy, libido, mood, brain fog), avoid the side effects by keeping levels monitored. That's not bad advice. But some of the specifics deserve a closer look, because the 100-150 ng/dL figure she drops is doing a lot of work here, and the evidence behind it is thinner than her confident delivery suggests.

Does the science back this up?

Mostly yes, but with important caveats. The androgenic side effects she lists are well-documented and dose-dependent. Acne and hair thinning from elevated androgens are supported by decades of dermatology literature. Voice changes and clitoral enlargement at supraphysiologic levels are real and can be irreversible.

What's less settled is the specific numerical threshold. There is no universally agreed-upon serum testosterone level above which virilization becomes inevitable in women. The Endocrine Society's 2014 clinical practice guideline (Wierman et al., Journal of Clinical Endocrinology and Metabolism) explicitly states that no validated safe upper limit exists for testosterone therapy in women. The ISSWSH and British Menopause Society guidelines suggest keeping total testosterone within or slightly above the normal female physiologic range, but they define that range variably. The 100-150 ng/dL figure Dr. Hirsch cites isn't derived from a randomized trial. It reflects reasonable clinical judgment, not hard data.

On pellets specifically: Glaser et al. (2013, Maturitas) found pellet delivery produced significantly higher and more variable testosterone levels compared to topical formulations, which is a legitimate pharmacokinetic concern. The inability to reverse a pellet dose if levels spike is a real clinical problem that her brief warning was right to flag.

What did they get wrong (or right)?

She got the side effect list right. Acne, hair loss, voice deepening, and clitoral enlargement are all documented androgenic effects, and the permanence warning for the last two is accurate and important. Give her credit for that, because a lot of wellness content glosses over these entirely.

Where she's on shakier ground is presenting "over 100 or 150" as though it's a published clinical cutoff. It isn't. Individual sensitivity to androgens varies considerably based on androgen receptor polymorphisms (Zitzmann, 2009, Molecular and Cellular Endocrinology). A woman can develop acne or hair thinning at levels well within the "normal" range if her receptors are particularly sensitive. Another woman might tolerate higher levels without virilizing symptoms. Presenting a single number gives false precision.

The pellet critique is fair but underexplained. She says symptoms "can be especially worse on pellet therapy" without explaining why, which leaves viewers with a warning but no framework to evaluate it. The core issue is that pellets are not adjustable once implanted, so if levels spike, you're stuck waiting weeks for the pellet to metabolize down. That's a pharmacokinetic reality, not a scare tactic.

What should you actually know?

Testosterone therapy for women is genuinely under-studied. The FDA has not approved any testosterone product specifically for women in the United States, which means everything being prescribed is off-label. That's not a red flag in itself, but it does mean the evidence base is thinner than for estrogen-based therapies.

If you're on or considering testosterone therapy, the key practical points are these. First, insist on regular serum testing. Total testosterone, free testosterone, and SHBG levels should be monitored, not just total T alone. Second, route of administration matters for dose stability. Topical gels and creams allow for dose adjustment; pellets do not. Third, symptoms like new acne or hair thinning are early warning signs worth reporting immediately, not dismissing.

The 2019 Global Consensus Position Statement on testosterone therapy in women (Davis et al., Journal of Clinical Endocrinology and Metabolism) is probably the most rigorous current reference. It supports use for hypoactive sexual desire disorder with a reasonable safety profile at physiologic doses, but it also explicitly does not endorse supraphysiologic dosing or pellet-specific protocols. Worth reading if you want the actual evidence rather than a TikTok summary.